Kardigan is a clinical-stage precision cardiovascular company advancing three late-stage programs, using its Prolaio data and analytics platform to support drug development. This filing changes governance, not the operating plan. Doug Giordano leaves the board and Audit Committee, while Kristin Reinke joins as a Class I director and takes the audit-chair role, effective September 29, 2026. 〔0〕 〔1〕
The replacement strengthens public-company finance oversight, but offers no clinical proof. Reinke is a Google vice president of finance, a CPA, and was designated independent and an SEC “financial expert.” 〔2〕 That is relevant as Kardigan moves from IPO-funded development toward potential commercialization, but the filing gives no new data, regulatory milestone, financing, or change to trial timing. The company’s stated rationale ties her technology and finance background to integrating Prolaio and guiding the late-stage pipeline, which is strategic support rather than an advancement of those programs.
The cost is visible but not thesis-changing. Reinke receives an initial non-qualified stock-option grant valued at $650,000 plus cash compensation under the director policy. The grant creates some dilution and compensation expense, but the filing provides no share count or terms that would make the magnitude assessable.
Bottom line: This is a credible audit-committee upgrade during Kardigan’s transition into a public, late-stage biotech, but it does not change the pipeline’s evidence, timing, or funding story. It is governance news, not a business milestone.
Read the original 8-K on SEC EDGAR ↗